Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $24.00 | Buy | Needham |
8/9/2024 | Outperform → In-line | Imperial Capital | |
5/22/2024 | $16.00 → $20.00 | Buy → Neutral | Citigroup |
4/16/2024 | $17.00 → $15.00 | Buy → Hold | Jefferies |
4/10/2024 | $20.00 | Buy | Canaccord Genuity |
2/28/2024 | $16.00 | In-line → Outperform | Imperial Capital |
2/26/2024 | $10.00 | Market Perform | Leerink Partners |
12/7/2023 | $9.00 | In-line | Imperial Capital |
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
424B7 - Hims & Hers Health, Inc. (0001773751) (Filer)
S-3ASR - Hims & Hers Health, Inc. (0001773751) (Filer)
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Pho
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management tea
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Pho
Manuel joins Hims & Hers board of directors to help the company further innovate and increase access to healthcare for millions within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. This press release features multimedia. View the full release here: https://www.businesswire.com
Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403772620/en/Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space. (Photo: Business Wire) "Christopher brings extensive experience working dir
Hims & Hers Health, Inc. (NYSE:HIMS) saw a notable surge in its stock Tuesday possibly from continued momentum from yesterday. Here’s what you need to know. What To Know: The company is scheduled to release its second-quarter earnings report on August 5th, after market close. The company's estimated earnings per share (EPS) for the quarter stands at 4 cents, with revenue projections at approximately $299.9 million What Else: In a significant development for the pharmaceutical industry, Novo Nordisk's weight-loss drug Wegovy has received expanded approval in the UK. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has now approved Wegovy not just for obesity treatment b
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
- Bloomberg
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management tea
Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com. "We are pleased to begin the year with exceptional results and strong momentum throughout the busines
Needham initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $24.00
Imperial Capital downgraded Hims & Hers Health from Outperform to In-line
Citigroup downgraded Hims & Hers Health from Buy to Neutral and set a new price target of $20.00 from $16.00 previously
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)